Receptors, Dopamine D1 < Receptors, Dopamine D2 < Receptors, Dopamine D3

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 42.
[0-20] [0 - 20][0 - 42][20-40]

Ident.	Authors (with country if any)	Title
000174 (2016)	R. Magnard ; Y. Vachez ; C. Carcenac ; P. Krack ; O. David ; M. Savasta ; S. Boulet ; S. Carnicella	What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?
000543 (2014)	S. Carnicella ; G. Drui ; S. Boulet ; C. Carcenac ; M. Favier ; T. Duran ; M. Savasta	Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.
000545 (2014)	Annalisa Fico ; Antoine De Chevigny ; Christophe Melon ; Manon Bohic ; Lydia Kerkerian-Le Goff ; Flavio Maina ; Rosanna Dono ; Harold Cremer	Reducing glypican-4 in ES cells improves recovery in a rat model of Parkinson's disease by increasing the production of dopaminergic neurons and decreasing teratoma formation.
000735 (2013)	Stéphane Thobois ; Eugénie Lhommée ; Hélène Klinger ; Claire Ardouin ; Emmanuelle Schmitt ; Amélie Bichon ; Andrea Kistner ; Anna Castrioto ; Jing Xie ; Valerie Fraix ; Pierre Pelissier ; Stephan Chabardes ; Patrick Mertens ; Jean-Louis Quesada ; Jean-Luc Bosson ; Pierre Pollak ; Emmanuel Broussolle ; Paul Krack	Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.
000799 (2013)	Michel Engeln ; Serge H. Ahmed ; Caroline Vouillac ; François Tison ; Erwan Bezard ; Pierre-Olivier Fernagut	Reinforcing properties of Pramipexole in normal and parkinsonian rats.
000896 (2012)	Jean-Antoine Girault	Integrating neurotransmission in striatal medium spiny neurons.
000A32 (2010)	Mark J. Millan	From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.
000A78 (2010)	A. Faure ; P. Leblanc-Veyrac ; N. El Massioui	Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism.
000B10 (2010)	Jacques Darcourt ; Jan Booij ; Klaus Tatsch ; Andrea Varrone ; Thierry Vander Borght ; Ozlem L. Kapucu ; Kjell N Gren ; Flavio Nobili ; Zuzana Walker ; Koen Van Laere	EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2.
000C89 (2008)	Gaëlle Bouchez ; Luc Sensebé ; Patrick Vourc'H ; Lucette Garreau ; Sylvie Bodard ; Angélique Rico ; Denis Guilloteau ; Pierre Charbord ; Jean-Claude Besnard ; Sylvie Chalon	Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.
000C91 (2008)	Virginie Czernecki ; Michael Schüpbach ; Sadek Yaici ; Richard Lévy ; Eric Bardinet ; Jérôme Yelnik ; Bruno Dubois ; Yves Agid	Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom.
000E28 (2006)	Mauricette Brocco ; Anne Dekeyne ; Mariusz Papp ; Mark J. Millan	Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
000F49 (2005)	C. Guigoni ; I. Aubert ; Q. Li ; V V Gurevich ; J L Benovic ; S. Ferry ; U. Mach ; H. Stark ; L. Leriche ; K. H Kansson ; Bernard H. Bioulac ; Christian E. Gross ; Pierre Sokoloff ; Gilberto Fisone ; E V Gurevich ; Bertrand Bloch ; Erwan Bezard	Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
000F62 (2005)	Emiliana Borrelli	Without DJ-1, the D2 receptor doesn't play.
000F88 (2004)	Stéphane Thobois ; François Vingerhoets ; Valerie Fraix ; Jing Xie-Brustolin ; Hélène Mollion ; Nicolas Costes ; Patrick Mertens ; Alim-Louis Benabid ; Pierre Pollak ; Emmanuel Broussolle	Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study.
001041 (2004)	Igor Sibon ; François Tison	Vascular parkinsonism.
001055 (2003)	A. Courtière ; J. Hardouin ; A. Goujon ; F. Vidal ; T. Hasbroucq	Selective effects of low-dose dopamine D1 and D2 receptor antagonists on rat information processing.
001068 (2003)	Olivier Guillin ; Nathalie Griffon ; Erwan Bezard ; Ludovic Leriche ; Jorge Diaz ; Christian Gross ; Pierre Sokoloff	Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease.
001076 (2003)	S. Thobois ; V. Fraix ; M. Savasta ; N. Costes ; P. Pollak ; P. Mertens ; A. Koudsie ; D. Le Bars ; A L Benabid ; E. Broussolle	Chronic subthalamic nucleus stimulation and striatal D2 dopamine receptors in Parkinson's disease--A [(11)C]-raclopride PET study.
001100 (2003)	Erwan Bézard ; Sandrine Ferry ; Ulrich Mach ; Holger Stark ; Ludovic Leriche ; Thomas Boraud ; Christian Gross ; Pierre Sokoloff	Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
001114 (2003)	Erwan Bezard ; Christian E. Gross ; Jonathan M. Brotchie	Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/MedMesh.i -k "Receptors, Dopamine D2" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/MedMesh.i  \
                -Sk "Receptors, Dopamine D2" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Receptors, Dopamine D2
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024